Statement to members 31/07/17
The Sunday Times released an inaccurate article 30.7.2017 which may have caused confusion as to the safety of HRT. We would like to reassure our members that our advice remains unchanged and in accordance with current guidelines1.
In women with POI, HRT is safe and is recommended to be taken until at least the natural age of menopause.
Estrogen is important for the normal functioning of a woman’s body. Reduced estrogen levels, not only result in menopausal symptoms, but can also affect the health of bones, heart and brain.
HRT aims to restore the levels of naturally depleted hormones in the body to a similar level as women of the same age without POI.
HRT has not been found to increase the risk of breast cancer in women with POI1.
One of our trustees previously worked as an HRT product brand manager. We would like to reassure members that this had no influence on our decision making and all recommendations are in line with national and international guidelines.
1Management of women with Premature Ovarian Insufficiency. Guideline of the European Society of Human Reproduction and Embryology (ESHRE, 2015). www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx